Evaluation and Credit: https://www.surveymonkey.com/r/MedChat18

 

Target Audience           

This activity is targeted toward Primary care specialties and psychiatrists.

Statement of Need

Promising research is being conducted on psychedelics for the treatment of psychiatric disorders.  Providers should be aware of emerging treatments. This podcast will address the research base and clinical use of psychedelics in the United States. Providers will be informed on the potential for use in practice in the future.

Objectives

At the conclusion of this offering, the participant will be able to:

• Review the history of psychedelics.
• Discuss the chemical and pharmacological properties of psychedelics.
• Describe the clinical use of psychedelics in the United States, including clinical trials.

 

Moderator

John J. Wernert, M.D., MHA, DLFAPA Executive Medical Norton Behavioral Medicine

 

Speaker

Christopher D. Bojrab, M.D., DFAPA President Indiana Health Group Carmel, Indiana

 

Speaker Disclosure

The speaker has the following conflicts of interest to disclose:  Consultant and Speakers Bureau – Allergan, Assures/Myriad, Neurocrine, Otsuka, Sunovion, Takeda and Teva. All relevant relationships have been successfully resolved.

Moderator and Planner Disclosures 

The moderator and planners for this activity have no potential or actual conflicts of interest to disclose.

Commercial Support 

This activity has not received commercial support.

 

Continuing Education Credits

American Medical Association

 

Accreditation

Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.

 

Designation

Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Kentucky Board of Nursing

Kentucky Board of Nursing (KBN) Approved Provider: Norton Healthcare, provider number 4-0002-12-20-245. The program has been approved by Norton Healthcare for 0.6 contact hours which expires 12/31/2020. KBN approval of a continuing education provider does not constitute endorsement of program content. Nursing participants must attest to the number of hours of attendance and complete the evaluation to receive contact hours.

For more information related to nursing credits, contact Sally Sturgeon DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org

 

Date of Original Release | September 2020

Course Termination Date | September 30, 2022 

Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org

 

 

Resources for Additional Study 

 

Chi, Tingying and Gold Jessica A., A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses, Journal of the Neurological Sciences, Volume 411, 15, April 2020. https://www.sciencedirect.com/science/article/pii/S0022510X20300514?via%3Dihub 

Krediet, Erwin, et.al., Reviewing the Potential of Psychedelics for the Treatment of PTSD, International Journal of Neuropsychopharmacology, March 20, 2020. https://academic.oup.com/ijnp/article/23/6/385/5805249

Romeo, Bruno, et. al, Efficacy of psychedelic treatments on depressive syndromes: A meta-analysis, Journal of Psychopharmacology, May 25, 2020.  https://journals.sagepub.com/doi/10.1177/0269881120919957